Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Dow
Healthtrust
Citi
Johnson and Johnson
QuintilesIMS
Teva
UBS
Daiichi Sankyo
Accenture

Generated: October 18, 2017

DrugPatentWatch Database Preview

Shire Orphan Therap Company Profile

« Back to Dashboard

What is the competitive landscape for SHIRE ORPHAN THERAP, and when can generic versions of SHIRE ORPHAN THERAP drugs launch?

SHIRE ORPHAN THERAP has one approved drug.

There is one US patent protecting SHIRE ORPHAN THERAP drugs on SHIRE ORPHAN THERAP drugs in the past three years.

There are one hundred and twelve patent family members on SHIRE ORPHAN THERAP drugs in thirty-three countries and six supplementary protection certificates in five countries.

Summary for Applicant: Shire Orphan Therap

International Patents:112
US Patents:1
Tradenames:1
Ingredients:1
NDAs:1
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Shire Orphan Therap
FIRAZYR
icatibant acetate
INJECTABLE;SUBCUTANEOUS022150-001Aug 25, 2011RXYesYes► Subscribe► Subscribe► Subscribe
Shire Orphan Therap
FIRAZYR
icatibant acetate
INJECTABLE;SUBCUTANEOUS022150-001Aug 25, 2011RXYesYes► Subscribe► Subscribe► Subscribe
Shire Orphan Therap
FIRAZYR
icatibant acetate
INJECTABLE;SUBCUTANEOUS022150-001Aug 25, 2011RXYesYes► Subscribe► SubscribeYY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for SHIRE ORPHAN THERAP drugs

Drugname Dosage Strength Tradename Submissiondate
icatibant
Injection10 mg/mL
FIRAZYR
8/25/2015

International Patent Family for Shire Orphan Therap Drugs

Country Document Number Estimated Expiration
Czech Republic280682► Subscribe
Ireland902923► Subscribe
Czechoslovakia9003979► Subscribe
Hungary911392► Subscribe
Hong Kong1006843► Subscribe
JapanH0386898► Subscribe
Germany58907889► Subscribe
Norway903545► Subscribe
Spain2065445► Subscribe
Portugal91692► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Shire Orphan Therap Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0359Netherlands► Subscribe300359, 20091121, EXPIRES: 20141120
/2008Austria► SubscribePRODUCT NAME: ICATIBANT, WAHLWEISE IN FORM EINES PHYSIOLOGISCH ANNEHMBAREN SALZES, EINSCHLIESSLICH ICATIBANT-ACETAT; REGISTRATION NO/DATE: EU/1/08/461/001 20080711
C0002France► SubscribePRODUCT NAME: ICATIBANT, EVENTUELLEMENT SOUS FORME DE SEL PHYSIOLOGIQUEMENT ACCEPTABLE, NOTAMMENT L?ACETATE D?ICATIBANT; REGISTRATION NO/DATE IN FRANCE: EU/1/08/461/001 DU 20080711; REGISTRATION NO/DATE AT EEC: EU/1/08/461/001 DU 20080711
C/GB09/002United Kingdom► SubscribePRODUCT NAME: ICATIBANT, OR A PHYSIOLOGICALLY TOLERABLE SALT THEREOF, INCLUDING ICATIBANT ACETATE; REGISTERED: UK EU/1/08/461/001 20080711
499Luxembourg► Subscribe91499, EXPIRES: 20141121
00359Netherlands► SubscribePRODUCT NAME: ICATIBANT, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, BIJ VOORKEUR ICATIBANTACETAAT; REGISTRATION NO/DATE: EU/1/048/461/001 20080711
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
Cipla
Harvard Business School
Cerilliant
Farmers Insurance
McKesson
Chinese Patent Office
Fish and Richardson
Deloitte
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot